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Abstract 
Background: Ecstasy use is associated with cognitive impairment, believed to result from 
damage to 5-HT axons. Neuroimaging techniques to investigate executive dysfunction in 
ecstasy users provide a more sensitive measure of cognitive impairment than behavioural 
indicators. The present study assessed executive access to semantic memory in ecstasy 
polydrug users and nonusers. Methods: Twenty ecstasy polydrug users and 20 non-user 
controls completed an oral variant of the Chicago Word Fluency Test (CWFT), whilst the 
haemodynamic response to the task was measured using functional Near Infrared 
Spectroscopy (fNIRS). Results: There were no between group differences in many 
background measures including measures of sleep and mood state (anxiety, arousal, hedonic 
tone). No behavioural differences were observed on the CWFT. However there were 
significant differences in oxy-Hb level change at several voxels relating to the left DLPFC 
and right medial PFC during the CWFT, indicating increased cognitive effort in ecstasy users 
relative to controls. Regression analyses showed that frequency of ecstasy use, total lifetime 
dose and amount used in the last 30 days were significant predictors of oxy-Hb increase at 
several voxels after controlling for alcohol and cannabis use indices. Conclusion: The results 
suggest that ecstasy users show increased activation in the PFC as a compensatory 
mechanism, to achieve equivalent performance to non-users. These findings are in agreement 
with much of the literature in the area which suggests that ecstasy may be a selective 
serotonin neurotoxin in humans. 
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Introduction 
 Ecstasy (MDMA/3,4-methylenedioxymethamphetamine) remains a popular 
recreational drug, with 3.3% of 16-24 year olds in the UK reporting use in the last year 
(Crime Survey of England and Wales, 2013), and lifetime prevalence across Europe 
remaining at around 7% for all age groups (European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA, 2013). Its popularity is of concern given the negative psychological 
and physiological consequences associated with continued use, that may have real world 
functional significance.  
 The increase in the monoamines serotonin, dopamine and norepinephrine after 
administration are the primary cause of its acute psychological and physiological effects 
(McDowell & Kleber, 1994).  After regular use, down regulation of serotonin receptors may 
be seen in humans, similar to that proposed in animal models (Reneman et al., 2002). More 
chronic continued use can cause serotonergic neurotoxicity, which may be long lasting. 
Evidence from SPECT studies reporting upregulation of 5-HT2A receptors following chronic 
use, suggests that the brain is attempting to compensate for loss of receptors due to 
neurotoxicity (Di Iorio et al., 2012; Reneman et al., 2002; Urban et al., 2012). Animal 
literature has provided evidence for MDMA related neurotoxicity (Molliver et al., 1990; 
Ricaurte et al., 1988). Furthermore, in humans, several studies suggest alterations to 
serotonergic functioning as a result of ecstasy use, for example SERT binding ratios are 
regularly observed to show alterations in ecstasy users relative to controls (Reneman, Booij et 
al., 2000; Reneman, Habraken et al., 2000). 
 Various executive tasks regularly yield little evidence for ecstasy related deficits, for 
example the Wisconsin Card Sorting Task (Fox et al., 2001; Back-Madruga et al., 2003), 
whereas others more consistently show evidence of diminished performance, such as the 
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computation span task (Fisk et al., 2004). This inconsistency was explored by Montgomery et 
al. (2005), using Miyake et al.’s (2000) conceptual framework of executive functioning, 
along with the additions made by Fisk and Sharp (2004), finding that updating and access to 
semantic memory were affected by ecstasy use. Access describes the efficiency with which 
words and semantics can be retrieved from long term memory. Damage to frontal regions 
produces significant impairment to word fluency ability (Stuss et al.,1998). In ecstasy users, 
fluency is significantly impaired using the Chicago Word Fluency Test (CWFT) 
(Montgomery et al., 2005), and this was more pronounced with increased difficulty. Ecstasy 
users have also shown deficits on a composite measure of word fluency (Montgomery et al., 
2007), verbal and semantic fluency (Heffernan et al., 2001), and access performance 
compared to cannabis users and controls after controlling for differences in sleep (Fisk & 
Montgomery, 2009). Conversely, an oral word fluency task (Controlled Oral Word 
Association Task - COWAT) has been less consistent in producing ecstasy related deficits. 
Several studies have reported no observable differences between ecstasy users and controls 
using this measure (Bedi & Redman, 2008; Halpern et al., 2004; Halpern et al., 2011; 
Morgan et al., 2002). However Bhattacharay and Powell (2001) observed ecstasy related 
deficits using the COWAT, and Croft et al. (2001) observed differences between a combined 
drug user group and controls on the semantic fluency measure of the task, whereby 
participants were asked to recall as many ‘animals’ as possible in one minute. However the 
authors suggest that the deficits may be more related to cannabis use than ecstasy use after 
covariate analysis.  
 One possible explanation as to why deficits are more consistently reported in the 
CWFT than the COWAT is that the CWFT involves production of words over 5 and 4 minute 
periods whereas the COWAT requires verbal responses over a one minute period. It could be 
that ecstasy related deficits become more apparent after long periods of sustained load on the 
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central executive. In addition, the more subtle cognitive deficits that result from chronic 
ecstasy use may not always be detectable using behavioural measures alone. Recently, 
neuroimaging measures have been combined with behavioural tasks, as an objective measure 
of performance. Roberts et al. (2013) observed ecstasy related alterations in cognitive 
processing from ERP measures during a semantic retrieval task. This study proposed that 
EEG correlates reflected evidence of cognitive reallocation/compensatory mechanisms in 
ecstasy users to perform at a similar level to controls. Furthermore this study also showed that 
these neurophysiological changes were a function of task difficulty. Similarly, in an fMRI 
study, Raj et al. (2010) observed BOLD signal change during a semantic recognition task in 
ecstasy polydrug users. There were significant correlations between ecstasy use and BOLD 
signal change in left BA9, 18 and 21/22 during recognition, but not encoding phases of the 
task. The authors suggested that these results provide evidence that semantic memory is 
affected by ecstasy use, despite ecstasy use not being correlated with performance. Studies 
such as these reflect the increased sensitivity of neuroimaging measures to detect cognitive 
alterations than behavioural measures alone. 
fNIRS is an emerging non-invasive neuroimaging tool measuring cerebral blood flow 
which can be used to assess the haemodynamic response to mental demand. More specifically 
fNIRS uses wavelengths of light in the near infrared range to assess levels of oxygenated 
(oxy) and deoxygenated haemoglobin (deoxy-Hb) in the prefrontal cortex (PFC). Due to 
fNIRS having a penetration depth of 2-3mm (Firbank et al., 1998), it images relatively 
superficial layers of the cortex. Nevertheless, areas of the PFC are easily accessed, therefore 
fNIRS is ideal for observing neurological activation during tasks that load on the 
(Dorsolateral) PFC. Increases in oxy-Hb are accepted as reflecting an increase in neuronal 
activity in certain brain regions (Leff et al., 2011). Furthermore it is hypothesised that 
although blood oxygenation is expected to increase with increased workload, this is only if 
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the participant is engaged in the task, whereas if the task becomes too difficult and attention 
shifts (as well as performance decline), a decrease in oxygenation will be observed (Izzetoglu 
et al., 2004). The distribution of the activation response is regionally specific i.e. the cortical 
regions underlying the voxels at which the activation is observed are responsible for the 
activation (Leff et al., 2011). Often an increase in oxy-Hb is coupled with a decrease in 
deoxy-Hb (Ehlis et al., 2008; Leff  et al., 2008; Leff et al., 2011). However the relationship 
between oxy and deoxy-Hb is non-linear and as such estimates of total blood volume are also 
sometimes calculated as a correlate of neuronal activation (Ayaz et al., 2012).   
The present study sought to investigate the cortical haemodynamic change when 
performing a semantic access task, in ecstasy polydrug users and non-user controls. 
Performance and haemodynamic response were measured on each level of the semantic task. 
It was hypothesized that ecstasy users would find the task more demanding than controls, 
shown by increased oxygenation relative to controls, but that behavioural differences would 
be negligible.    
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Method 
Design: 
For the CWFT, a mixed design was used with group as the between groups factor (2 levels – 
ecstasy user, nonuser), level of difficulty as the within groups factor (animals, S letter, C 
letter) and number of words produced as the dependent variables. For fNIRS analysis group 
with 2 levels (ecstasy user, nonuser) was the between groups variable and mean oxygenated 
haemoglobin change at each voxel (1-16) for each level of difficulty was the dependent 
variable.  
 Participants: 
Twenty ecstasy users (mean age = 21.85±2.76; 13 = male) and 20 non-user controls 
(mean age = 20.89±2.05; 8 = male) were recruited via email to university students. Inclusion 
criteria for the ecstasy using group were: use of ecstasy on at least 5 occasions (actual 
minimum = 11); indices of ecstasy use were as follows: total lifetime dose 431.75 tablets ± 
885.08; mean amount used in last 30 days 2.55 tablets ± 3.23, and frequency of use 0.37 
times/week ± 0.51. To be included in the nonuser group, participants must have never used 
ecstasy; the nonuser group mainly consisted of drug naïve participants. All participants were 
required to be drug free for 7 days prior to testing (confirmed via self-report), and must report 
no current or past-year diagnosis of a psychological disorder (e.g. GAD, Major Depressive 
Disorder), and no current use of medications aside from the contraceptive pill and occasional 
non-prescription painkiller use.  
Materials 
Questionnaires: 
Participants completed a number of questionnaires including:  
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Background Drug Use Questionnaire from which information about drug use (frequency of 
use, last 30 days use, first and last use, patterns of use) and other lifestyle variables, as well as 
socio-demographic variables is obtained. Using a method employed by Montgomery et al. 
(2005) estimates of total lifetime use of each drug were calculated, as well as totals for last 30 
days drug use and weekly drug use estimates. 
Measures of Sleep Quality: 
Various questionnaires assessing alertness and sleep quality were administered to participants 
to investigate any potential relationship between sleep and cognition. The Epworth Sleepiness 
Scale (ESS; Johns, 1991) which explores the likelihood of dozing or falling asleep in various 
situations was used to measure subjective daytime sleepiness (high score = sleepiness). The 
Morningness-Eveningness Questionnaire (MEQ; Termann et al., 2001) is a self-assessment 
of morningness-eveningness in human circadian rhythms. A high MEQ score indicates a 
morning type person, whereas a low score indicates and evening type person. The Karolinska 
Sleepiness Scale (KSS; Akerstedt & Gillberg, 1990) was used to assess sleepiness pre and 
post task. 
Mood State: 
State anxiety, arousal and hedonic tone were assessed using the scale devised by Fisk and 
Warr (1996). Ratings of mood on a Likert scale (1 = not at all, 5 = extremely), that relate to 
current mood at the time of testing were completed. A high score on each scale relates to 
increased hedonic tone/anxiety/arousal. 
 Raven’s Progressive Matrices (SPM; Raven, Raven, & Court, 1998) 
Ravens SPM was implemented to assess fluid intelligence. A series of problems (five sets of 
12, 60 in total), are presented as a symbolic sequence. Participants must select an appropriate 
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response to complete the sequence from a choice of 6/8 options. Each block of 12 problems 
starts with an intuitively simple problem and the difficulty of the problems increases as the 
task progresses. 
Access Task: 
The Chicago Word Fluency Task (Thurstone, 1938)    
This consisted of three blocks in which participants had to verbally produce as many words 
as they could in one minute. In the first block (semantic fluency), participants were instructed 
to name as many animals as they could. Following this they were instructed to produce as 
many words as possible beginning with the letter “S”, and in the third and final block they 
were required to name as many four letter words beginning with the letter “C” as possible. 
Participants were informed that place names, people’s names and plurals were prohibited. 
Responses were recorded on a cassette deck with a built in microphone. Scores for each of 
the fluency tasks were counted as the number of appropriate words in each case. 
Equipment 
A continuous wave fNIRS system (developed by Drexel University, Philadelphia, PA) 
supplied by Biopac systems (Goleta, CA, USA) was used for monitoring the haemodynamic 
response. A 16-channel fNIRS sensor was used with a temporal resolution of 2Hz, and a 
source-detector separation of 2.5cm allowing 1.25cm penetration depth (Ayaz et al., 2012). 
An fNIR100 control box and  COBI studio (Drexel university) were used for data acquisition 
and visualisation during data collection (as per Ayaz et al., 2011; Ayaz et al., 2012). 
Procedure 
Participants attended the lab for a single session lasting approximately 2 hours. Testing 
sessions commenced at 9am, 11am and 1pm and 3pm, with equal numbers of each group 
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tested at each session time. Upon arrival participants were given an information sheet 
explaining what was involved in the study, and written consent was obtained. Questionnaires 
were administered in the following order: background drug use questionnaire, MEQ, ESS, 
pre-test KSS, UMACL and Raven’s SPM. The fNIRS headband was then fitted to the 
participant’s forehead (See Figure 1 for voxel anatomical locations). fNIRS signals were 
displayed on a desktop computer running COBI studio (Drexel University) in an adjacent 
room to the testing room. Once fNIRS signals were stable, a 2-minute baseline of inactivity 
was recorded. Participants watched a video of planet earth accompanied by soothing music 
and the baseline was recorded during this period. Participants then completed the CWFT. 
After completing the task participants were given the post task KSS. Participants were fully 
debriefed after the testing procedure and were paid £20 in store vouchers. The study was 
approved by Liverpool John Moores University Research Ethics Committee, and was 
administered in accordance with the ethical guidelines of the British Psychological Society. 
fNIRS analysis 
fNIRS raw data from COBI studio was pre-processed using fnirSoft (Biopac systems; Goleta, 
CA, USA). Saturated channels were discarded after visual inspection. A high-pass filter 
(0.1Hz cut off) was applied for removal of noise due to respiration and a linear phase filter 
(order of 20) was used to remove high frequency noise (Ayaz et al., 2011; Ayaz et al., 2012). 
Oxy and deoxy-Hb changes from baseline for the 1-minute epochs measured were calculated 
for each of the 16 voxels using the modified Beer-Lambert law logarithm in fnirSoft (Ayaz et 
al., 2010).  
Results 
Socio-demographic information, sleep measures and scores of anxiety, hedonic tone and 
arousal are shown in Table 1. Indices of other drug and alcohol use are displayed in Table 2.  
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<<Insert Tables 1 & 2 Here>> 
t-tests on these background variables revealed there were no significant differences between 
the two groups in age t(36) = 1.21, p>.05, total scores on the ESS t(37) = -0.28, p>.05, MEQ 
t(30) = -.1.37, p>.05, Raven’s SPM t(38) = -0.41, p>.05, pre-test KSS t(38) = -0.88, p>.05, 
post-test KSS t(26) = 1.59, p>.05, or levels of arousal t(38) = -0.28, p>.05, hedonic tone t(38) 
= 0.41, p>.05 and anxiety t(38) = -0.07, p>.05. However ecstasy users did drink significantly 
more units of alcohol per week than non-users t(38) = 2.71, p<.01, and it is clear from Table 
2 that there is concomitant drug use in this cohort.  
 
Behavioural Data Analysis:  
In the behavioural data analysis and all fNIRS analyses, gender was included as a covariate 
due to uneven gender distribution between the groups in the present study, and to address 
possible gender differences in access to semantic memory performance (Loonstra et al., 
2001). Number of words produced at each level of difficulty in the CWFT is displayed in 
Table 3. A mixed ANOVA was conducted on the CWFT data with group as the between 
subjects variable and level of difficulty as the within subjects variable (in order of relative 
difficulty: animals < “S” letter < “C” letter), and gender as a covariate. There was a 
significant main effect of difficulty on the task F(1.58, 58.59) = 17.08, p<.01 (the sphericity 
assumption was violated so Greenhouse-Geisser adjusted stats are reported), however there 
was no gender by difficulty interaction F(1.58, 58.59) = 0.09, p>.05 and no group by 
difficulty interaction F(1.58, 58.59) = 0.57, p>.05. Furthermore there was no significant 
effect of group F(1,37) = 0.22, p>.05. 
    <<Insert Table 3 Here>> 
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fNIRS Analysis 
Averaged oxy and deoxy-Hb changes from baseline, over the one minute epochs for each 
level of the task can be observed in Figures 2 and 3. A series of ANOVAs1 were conducted to 
assess group differences in oxy and deoxy-Hb changes from baseline for each block of the 
task. Analysis of oxy-Hb change in block one of the CWFT (“animals”) revealed that after 
controlling for gender differences, ecstasy users displayed a significant increase in oxy-Hb 
compared to controls at V2 F(1,36) = 8.50, p<.01, V3 F(1,35) = 8.42, p<.01, V4 F(1,18) = 
4.21, p<.05, V10 F(1,30) = 6.54, p<.05, V11 F(1,23) = 12.79, p<.05 and V16 F(1,17) = 3.96, 
p<.05. Differences were approaching significance at V5 F(1,36) = 7.76, p=.06, V12 F(1,32) = 
3.82, p = .06 and V13 F(1,36) = 3.24, p = .08. All other differences were non-significant 
(p>.05). ANOVA on the deoxy-Hb data revealed that ecstasy users showed greater 
deoxygenation compared to controls at V2 F(1,36) = 5.70, p<.05 and V4 F(1,17) = 4.60, 
p<.05. No other differences were observed for any other voxel measured (p>.05 in each case).  
<<Insert Figure 2 Here>> 
After controlling for gender, naming words beginning with the letter “S” yielded significant 
increases in oxy-Hb change in ecstasy users relative to controls at V3 F(1,35) = 6.02, p<.05, 
V4 F(1,17) = 5.78, p<.05, V10 F(1,30) = 11.13, p<.01 and V12 F(1,32) = 3.65, p>.05. This 
difference was also approaching significance at V2 F(1,36) = 3.51, p = .06. There were no 
significant between group differences at any of the other voxels measured (p>.05 in each 
case). After controlling for gender, ANOVA on deoxy-Hb change revealed ecstasy users had 
significantly greater deoxy-Hb at V4 F(1,17) = 4.34, p<.05, with trends at V2 F(1,36) = 3.94, 
p = .06 and V14 F(1,36) = 3.51, p = .07. There were no significant differences at any of the 
other voxels measured (p>.05 in each case).  
                                                 
1 Due to small amounts of missing data on different optodes, MANOVA was not appropriate for this analysis.  
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<<Insert Figure 3 Here>> 
After controlling for gender, oxy-Hb change during the most demanding block (4-
letter C words) of this task revealed that ecstasy users displayed a significant increase in oxy-
Hb compared to controls at V3 F(1,35) = 4.77, p<.05, V4 F(1,17) = 5.04, p<.05, V10 F(1,30) 
= 9.64, p<.01 and V12 F(1,32) = 7.79, p<.01. Differences approached significance at V2 
F(1,37) = 3.52, p=.07. There were no significant differences at any of the other voxels 
measured (p>.05 in each case). There were no significant between group differences in 
deoxy-Hb change during this part of the task (p>.05 in all cases). However ecstasy users 
displayed greater deoxygenation compared to controls that was approaching significance at 
V2 F(1,36) = 3.09, p=.08 and V4 F(1,17) = 3.25, p=.08. There were no significant differences 
at any of the other voxels measured (p>.05 in each case). 
Overall these results show a general increase in oxy-Hb from baseline for ecstasy 
users compared to controls that is significant at several voxels in each level of the task. 
Due to the high level of cannabis and alcohol use amongst the ecstasy user group in 
the current sample, multiple regression analyses were conducted on the fNIRS data, at voxels 
showing between group differences, to observe whether ecstasy use predicted oxy-Hb level 
after controlling for cannabis use. Oxy-Hb (µmolar) change level was entered as the 
dependent variable in each case. In step one average weekly dose of alcohol use was entered, 
in step two indices of cannabis use were entered as predictors (frequency of use, total lifetime 
dose, recent use (amount taken in the last 30 days) and in step three the same indices of 
ecstasy use were entered as predictors. For brevity only regressions yielding significant 
results are reported here, and statistics associated with significant models are summarised in 
Table 4.  
<<Insert Table 4 Here>> 
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For Block 1 (animals) the regressions for V2, V10 and V16 oxy-Hb and V2 deoxy-Hb 
were non-significant so these are not discussed further. For the regression model predicting 
oxy-Hb at V3, the overall models for step 1 (alcohol) and step 2 (alcohol and cannabis) were 
non-significant, p>.05 in both cases. When indices of ecstasy use were added in step 3, the 
overall model was significant F(7,30) = 4.16, p<.01, accounting for 37.4% of the variance in 
oxy-Hb (after removing variance due to cannabis and alcohol use, ecstasy use indices 
accounted for an additional significant 18.9% of the variance). Average alcohol consumption 
and frequency of cannabis use emerged as significant predictors, and after removing variance 
due to these predictors, frequency of ecstasy use and total lifetime dose of ecstasy were 
significant individual predictors. For the regression model predicting oxy-Hb at V4, the 
overall models for step 1 (alcohol) and step 2 (alcohol and cannabis) were non-significant, 
p>.05 in both cases. When indices of ecstasy use were added in step 3, the overall model was 
significant F(7,19) = 6.03, p<.01., accounting for 78% of the variance in oxy-Hb (after 
removing variance due to cannabis and alcohol use, ecstasy use indices accounted for an 
additional significant 54.6% of the variance). Average alcohol consumption and total lifetime 
dose of cannabis emerged as significant predictors, and after removing variance due to these 
predictors, frequency of ecstasy use and total lifetime dose of ecstasy were significant 
individual predictors. For the regression model predicting oxy-Hb at V11, the overall models 
for step 1 (alcohol) and step 2 (alcohol and cannabis) were non-significant, p>.05 in both 
cases. When indices of ecstasy use were added in step 3, the overall model approached 
significance F(7, 19) = 2.42, p = 0.06., accounting for 48.5% of the variance in oxy-Hb (after 
removing variance due to cannabis and alcohol use, ecstasy use indices accounted for an 
additional significant 25.1% of the variance). Total lifetime dose of ecstasy was the only 
significant individual predictor. Finally the regression model predicting deoxy-Hb at V4 the 
overall models for step 1 (alcohol) and step 2 (alcohol and cannabis) were non-significant, 
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p>.05 in both cases. When indices of ecstasy use were added in step 3, the overall model was 
significant F(7,19) = 7.86, p<.01, accounting for 82.1% of the variance in deoxy-Hb (after 
removing variance due to cannabis and alcohol use, ecstasy use indices accounted for an 
additional significant 74.4% of the variance). Lifetime dose of cannabis and recent cannabis 
use emerged as significant predictors and after removing variance due to alcohol and 
cannabis, lifetime dose of ecstasy was a significant individual predictor.  
For block 2 of the task (S-letter words) the regressions for V10 and V12 oxy-Hb were 
non-significant so these are not discussed further. For the regression model predicting oxy-
Hb at V3, the overall models for step 1 (alcohol) and step 2 (alcohol and cannabis) were non-
significant, p>.05 in both cases. When indices of ecstasy use were added in step 3, the overall 
model was significant F(7,30) = 4.24, p<.01, accounting for 49.7% of the variance in oxy-Hb 
(after removing variance due to cannabis and alcohol use, ecstasy use indices accounted for 
an additional significant 36.6% of the variance). Average alcohol consumption emerged as a 
significant predictor, and after removing variance due to this, frequency of ecstasy use and 
total lifetime dose of ecstasy were significant individual predictors. For the regression model 
predicting oxy-Hb at V4, the overall models for step 1 (alcohol) and step 2 (alcohol and 
cannabis) were non-significant, p>.05 in both cases. When indices of ecstasy use were added 
in step 3, the overall model was significant F(7,19) = 5.79, p<.01, accounting for 77.2% of 
the variance in oxy-Hb (after removing variance due to cannabis and alcohol use, ecstasy use 
indices accounted for an additional significant 45.8% of the variance). Average alcohol 
consumption and lifetime dose of cannabis emerged as significant predictors, and after 
removing variance due to this, total lifetime dose of ecstasy and current use (last 30 days) 
were significant individual predictors. For the regression model predicting deoxy-Hb at V4, 
the overall models for step 1 (alcohol) and step 2 (alcohol and cannabis) were non-significant, 
p>.05 in both cases. When indices of ecstasy use were added in step 3, the overall model was 
16 
 
significant F(7,19) = 9.94, p<.01, accounting for 85.3% of the variance in deoxy-Hb (after 
removing variance due to cannabis and alcohol use, ecstasy use indices accounted for an 
additional significant 73.7% of the variance). Total lifetime dose of cannabis and recent 
cannabis use emerged as significant predictors, and after removing variance due to this, total 
lifetime dose of ecstasy was a significant individual predictors. 
For Block 3 (4-letter C words) the regressions for V10 and V12 oxy-Hb were non-significant 
so these are not discussed further. For the regression model predicting oxy-Hb at V3, the 
overall models for step 1 (alcohol) and step 2 (alcohol and cannabis) were non-significant, 
p>.05 in both cases. When indices of ecstasy use were added in step 3, the overall model was 
significant F(7,30) = 3.98, p<.01, accounting for 48.1% of the variance in oxy-Hb (after 
removing variance due to cannabis and alcohol use, ecstasy use indices accounted for an 
additional significant 38% of the variance). Average alcohol consumption emerged as a 
significant predictor, and after removing variance due to this, frequency of ecstasy use was a 
significant individual predictor. For the regression model predicting oxy-Hb at V4, the 
overall models for step 1 (alcohol) and step 2 (alcohol and cannabis) were non-significant, 
p>.05 in both cases. When indices of ecstasy use were added in step 3, the overall model was 
significant F(7,19) = 5.60, p<.01, accounting for 76.6% of the variance in oxy-Hb (after 
removing variance due to cannabis and alcohol use, ecstasy use indices accounted for an 
additional significant 48.7% of the variance). Average alcohol consumption, lifetime dose of 
cannabis and recent cannabis use emerged as significant predictors, and after removing 
variance due to this, lifetime dose of ecstasy and recent ecstasy use were significant 
individual predictors. 
The results indicate that ecstasy users consistently show significantly increased oxy-
Hb relative to controls over several voxels pertaining to the left DLPFC and right medial PFC 
during each block of the task. Ecstasy users also displayed significant increases in deoxy-Hb 
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compared to controls at V2 and V4 relating to the left DLPFC and left medial PFC in blocks 
one (animals) and two (“s” letter words). Ecstasy use indices remained as significant 
predictors of oxy and deoxy-Hb in the regression analyses after removing variance due to 
weekly alcohol consumption and cannabis use indices, with increased ecstasy use indicating 
increased oxy and deoxy-Hb change from baseline. However, alcohol use and indices of 
cannabis use did emerge as significant predictors of Hb-change in some of the regression 
analyses with increased use associated with increased oxy-Hb and deoxy-Hb change.  
Discussion  
This study investigated ecstasy related deficits in access, using performance indices and 
measures of haemodynamic response in the PFC with fNIRS in a sample of ecstasy polydrug 
users and non-user controls. The ecstasy users in the current sample did not differ 
significantly from controls in fluid intelligence, sleep measures or levels of arousal, 
depression or anxiety. However, they did report drinking significantly more alcohol per week 
than controls and due to their concomitant use of other drugs, it may be more appropriate to 
refer to them as polydrug users. 
The two groups in this study did not show performance differences at any level of the 
CWFT. However there were several between group differences in the fNIRS data that 
warrant discussion. Ecstasy users displayed increases in oxygenated haemoglobin compared 
to controls in three voxels relating to the left DLPFC (V2, V3, V4) as well as three voxels 
relating to the right medial and dorsolateral PFC (V10, V11, V16) on what is considered to be 
the easiest level of difficulty on the task (naming animals). In this block it should be noted 
that while behavioural differences were non-significant, there was a mean difference of 3.45 
words with ecstasy users performing better than nonusers, so these increases in oxygenation 
could be facilitating better performance, albeit non-significantly. As difficulty increased, 
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ecstasy users displayed a significantly greater increase in oxygenated haemoglobin relative to 
controls at two voxels (V3, V4) relating to the left DLPFC and a further two voxels relating 
to the right medial PFC (V10, V12). This increase in oxygenation is complimented by an 
increase in deoxygenation compared to controls at V4 in the left DLPFC (and V2 that was 
approaching significance) and V14 in the right DLPFC that was approaching significance. In 
the final and most difficult phase of the task (4 letter words beginning with C) ecstasy users 
display significant increases in oxygenated haemoglobin compared to controls at four voxels 
(V3, V4, V10, V12) and a further one voxel approaching significance (V2) that pertain to the 
left DLPFC and right medial PFC. 
 Thus ecstasy users show consistently increased levels of oxygenated haemoglobin in 
the LDLPFC and RPFC regions during the access executive function. However, there was no 
observed increase in oxygenation as a function of task difficulty as shown in previous 
research (Montgomery et al., 2005). This tentatively indicates that access to semantic 
memory may be an “all or nothing” process which requires a certain amount of neural 
resources to be activated, but this does not increase with increasing difficulty. In addition, 
increases in oxy-Hb to both the left and right hemispheres may reflect the need for more 
cognitive resources to attenuate behavioural performance decline. This is in line with 
previous reports from ERP (Roberts et al., 2013) and fMRI (Raj et al., 2010) studies that 
indicate atypical cognitive processing in ecstasy users, despite equivalent behavioural 
performance during semantic retrieval. This highlights the greater sensitivity of 
neurophysiological measures to detect cognitive impairment. It is possible that compensatory 
mechanisms may explain the lack of behavioural differences observed using similar tasks in 
the literature (Bedi & Redman, 2008; Halpern et al., 2004; Morgan et al., 2002), especially if 
we consider that these studies employed simpler word fluency measures than those yielding 
performance differences (e.g. Montgomery et al., 2005). Moreover Montgomery et al. (2005) 
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used a much longer time frame for generating words than the task employed in this study 
(and those in the studies mentioned above), suggesting that longer periods of sustained load 
on the central executive produce more pronounced effects.  
The importance of measuring haemodynamic response to tasks where subjects 
perform at a similar level behaviourally has been explored previously in human operators (for 
example, air traffic control operators – Ayaz et al., 2012). Such studies highlight the 
dissociation between cognitive effort and performance output, arguing that performance can 
be maintained at necessary levels via increased mental effort or perhaps strategic alterations. 
However increased mental workload is also predictive of future performance failure (with 
increased demand or task changes). Increases in oxy-Hb are accepted as increases in 
cognitive effort despite behaviourally similar performance, and can be used as an assessment 
of operators’ ability (Ayaz et al., 2012). Thus increasing cognitive effort to maintain similar 
behavioural performance may reflect recruitment of additional cognitive resources compared 
to controls, and predict future cognitive decline. This is likely to be more pronounced in 
recent users of the drug and future research should focus on investigating performance after 
prolonged abstinence.  
It is interesting to note the consistent increase in oxy-Hb in the left DLPFC and right 
medial PFC over all three levels of the task, given these areas have been implicated in 
semantic and word fluency previously. Stuss et al. (1998) observed that patients with lesions 
to the left DLPFC showed severe impairments on letter based word fluency measures. The 
same lesion sites produced impairments in category based fluency, but so did lesions to right 
medial and DLPFC regions. Indeed the left inferior frontal gyrus, has been consistently 
associated with semantic and phonologic processing in functional neuroimaging studies 
(Costafreda et al., 2006), so it is interesting that these areas should show the greatest 
differences in the word fluency task here. These areas show increased oxygenation indicating 
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increased effort in ecstasy users compared to controls to achieve similar performance. 
Likewise, Raj et al. (2010) observed that ecstasy users displayed cognitive processing 
aberrations that relate to areas of the DLPFC during semantic recognition, despite equivalent 
task performance, in an fMRI study, that is broadly consistent with the present findings.  
The idea that this differential pattern of functioning in the (DL)PFC reflects potential 
ecstasy-related neurotoxicity warrants further discussion. These forebrain structures are 
densely innervated with 5-HT neurons (Curtis & D’Esposito, 2003), thus alterations to 
functioning in these areas would be expected after repeated use of ecstasy if it is a selective 
serotonin neurotoxin in humans, as it is in animals (Green, 2003). This is in line with the 
findings of the current study, as well as other neuroimaging studies that have observed 
alterations to prefrontal areas in ecstasy users (Jager et al., 2008; Moeller et al., 2004; 
Roberts & Garavan, 2010). Further to this point, the three aforementioned fMRI studies 
(Jager et al., 2008; Moeller et al., 2004; Roberts & Garavan, 2010) all observe that ecstasy 
users display increased neuronal activity as a compensatory mechanism to achieve similar 
performance as controls despite being less efficient at the task.  
Curiously increases in oxy-Hb were complimented by increases in deoxy-Hb in the 
ecstasy user group in the current study. Moreover, increases in deoxy-Hb from baseline were 
significantly different from controls at V4, with trends at V2 and V14 during the second 
block of the task. Previous research has suggested that increases in oxy-Hb are often 
complimented by a decrease in deoxy-Hb in the same area (Ehlis et al., 2008; Leff et al., 
2008). However oxygenated and deoxygenated haemoglobin do not necessarily have a linear 
relationship, rather they are separate sources of haemodynamic response. Several studies 
have shown increases in deoxy-Hb alongside increases in oxy-Hb (Hoshi & Tamura, 1993; 
Sakatani et al., 1999). As such deoxy-Hb appears to be a less reliable measure of neuronal 
activation than oxy-Hb in fNIRS. Nevertheless these results are better understood as an 
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increase in total haemoglobin to the areas of the prefrontal cortex that are involved in this 
executive function, given that total-Hb is understood to be the sum of oxy-Hb and deoxy-Hb 
(Steinbrink et al., 2006).  
It is worthy of note that while the participants in the present study reported that 
ecstasy was their “drug of choice”, there was co-use of other drugs in the ecstasy user group. 
The most prominently co-used substance was alcohol with cannabis also being used by many 
participants. In the regression analyses, models that used alcohol alone or alcohol and 
cannabis were non-significant. However models including indices of ecstasy use were 
significant for changes in oxy- and deoxy-Hb at 9 voxels. Indices of ecstasy use were 
significant predictors on 14 occasions after removing any variance due to alcohol and 
cannabis. Nonetheless, in the 3rd step of the model, cannabis and alcohol did emerge as 
significant predictors on a number of occasions, lifetime dose of cannabis featured 
prominently in this respect. Previous research (Kiang et al., 2013) has shown that cannabis 
users have shown ERP abnormalities during semantic memory processing. Thus future 
research should seek to elucidate fully the relative roles of ecstasy and cannabis in semantic 
memory deficits.  
Despite the significant differences between ecstasy users and controls in this study, as 
with any study investigating cognitive deficits in ecstasy users, the results require caution 
during interpretation. Due to concomitant use of other drugs, it cannot be ruled out that other 
drugs or alcohol either alone or in conjunction with ecstasy may be responsible for the effects 
observed in this study. Attempts were made to statistically control for use of the most 
prominent co-used substances – alcohol and cannabis, using regression analyses. After 
controlling for alcohol and cannabis use indices, ecstasy use indices came out as significant 
predictors of oxy-Hb increase at several voxels, suggesting that use of ecstasy is most likely 
responsible for the observed differences. However in the absence of a pure ecstasy using 
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sample such as that used in Halpern et al. (2011), it is difficult to attribute the observed 
differences in the present study solely to ecstasy so the effects is best described as an ecstasy-
polydrug effect. Attempts have also been made to control for several potential confounds 
including fluid intelligence, sleep measures and levels of anxiety, depression and arousal, 
with no between group differences reported in any of these variables; however, a diagnostic 
psychiatric interview (e.g. the SCID) was not used in screening so future research should seek 
to rule out any underlying differences in psychopathology which may contribute to the 
observed effects. We also controlled for potential gender differences via ANCOVA, but in 
future, matching groups on this basis would be preferable. Self-report measures of 
background drug use, while frequently used in this research, may not be ideal given the 
implications of memory deficits associated with illicit drug use. It is also possible that 
substance users could lie on self-reports of drug use. However, we do not believe this to be 
the case in the present study as participants were not informed that they would be penalised 
for failing to meet these criteria. In recent work from our laboratory, a very low level of 
recent use was found in participants’ urine. Exclusion of participants testing positive for 
metabolites did not change the significant effects (Roberts et al., 2013). Furthermore, self-
reports of ecstasy use  are consistent with objective analysis of hair samples in ecstasy users 
(Scholey et al., 2011), thus we believe that while objective analysis of drug metabolites is 
desirable, the lack of this in the present study does not detract from the main significant 
findings. Also, the purity of ecstasy tablets consumed, as well as cocaine purity and cannabis 
strength cannot be verified. However, Parrott (2004) reported ecstasy tablets collected from 
amnesty bins in nightclubs in the UK were approaching 100%. Nevertheless, if this is no 
longer the case and the purity of MDMA in tablets consumed by participants in this study is 
much lower, then the magnitude of cognitive effects observed is of even greater concern. In 
addition even in low content MDMA tablets, the presence of Methylenedioxyamphetamine 
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(MDA), Methylenedioxyethylamphetamine (MDEA/MDE) and other compounds usually 
found in street ecstasy has been found to lengthen and strengthen the effects of the drug 
(Bexis & Docherty, 2006).  
The present study provides evidence of altered neuronal functioning in ecstasy 
polydrug users relative to controls during a task that taps the executive function of access. 
Significant increases in oxy-Hb over areas of the left DLPFC and right medial PFC during all 
levels of the task were observed in ecstasy users relative to controls that reflect compensatory 
mechanisms/recruitment of additional resources to achieve similar performance. These results 
suggest that ecstasy users are engaged in more effortful cognition than non-users, perhaps due 
to damage to the serotonergic system.  
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 Table 1: Indices sleep quality, fluid intelligence and socio-demographic variables 
 Ecstasy users 
 
 Non-users  
Males:  n, (%) 13 (65)   8 (40) 
Age (SD) 
 
21.85 (2.76) 20.89 (2.05) 
University 
degree: n (%) 
4 (20) 5 (25) 
   
Employment 
status 
  
Student; n, (%) 17 (85) 20 (100) 
Employed; n 
(%) 
2 (10) 0 (0) 
Unemployed; n 
(%) 
1 (5) 0 (0) 
   
      Mean (SD) Mean (SD) 
   
Ravens 
Progressive 
Matrices 
(maximum 60) 
47.20 (5.64) 48.00 (6.79) 
   
ESS Score 
(maximum 24) 
 
5.00 (2.81) 5.25 (2.81) 
KSS before 4.30 (1.49) 4.75 (1.74) 
   
KSS after 5.33 (2.15) 4.06 (2.05) 
   
MEQ total 45.33 (9.31) 50.00 (9.95) 
   
UWIST anxiety 8.70 (2.56) 8.75 (2.24) 
   
UWIST 
depression  
 
9.05 (3.22) 8.70 (2.00) 
   
UWIST arousal 17.35 (5.38) 17.75 (3.29) 
 
Weekly alcohol 
use (UK units) 
 
18.68(11.91) 
 
9.75(8.63) 
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Table 2: Indices of drug use 
 Ecstasy users Nonusers 
 Mean  SD N Mean  SD N 
Cannabis       
Frequency (times/wk) 1.42  1.94 19 0.04 - 1 
Last 30 days (joints) 23.03  40.19 19 1 - 1 
Total use (joints) 1607.88  2212.54 19 2  1 
       
Cocaine       
Frequency (times/wk) 1.15  2.96 11    
Last 30 days (lines) 6.42  6.42 12    
Total use (lines) 294.64  294.64 14    
       
Ketamine       
Frequency (times/wk) 0.24  0.32 10    
Last 30 days use (grams) 0.33  0.71 9    
Total use (grams) 7.16  9.56 11    
       
Abstinence (weeks)       
Ecstasy 17.40 29.96 20    
Cannabis 21.25 71.55 19 2 - 1 
Cocaine 16.00 28.49 14    
Ketamine 27.57 31.30 11    
LSD 101.60 104.79 5    
       
Ever used (N)       
Cannabis   19    
Cocaine   14    
Ketamine   11    
LSD   5    
Poppers   10    
Viagra   2    
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Table 3: Means and SDs for CWFT scores for ecstasy users and non-users 
     Ecstasy users           Non-users 
 Mean (SD)  Mean (SD)  
     
CWFT     
Animals 42.10 (9.24)  38.55 (7.27)  
Words beginning with “S” 37.95 (11.26)  35.75 (11.49)  
4 letter words beginning with “C” 15.45 (7.12)  15.55 (8.17)  
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Table 4: Summary of Regression analyses.  
 
Dependent Model  R2% Predictor β t p 
Animals:        
V3OxyHb 1 7.2 Average alcohol 
Cannabis frequency 
Ecstasy frequency 
Lifetime dose ecstasy 
 
-0.53 
0.42 
0.55 
0.38 
-3.31 
2.46 
3.25 
2.16 
<.01 
<.05 
<.01 
<.05 
 2 18.5 
 3 37.4 
V4OxyHb 1 
2 
3 
6.1 
20.3 
78.0 
Average alcohol 
Lifetime dose cannabis 
Ecstasy frequency 
Lifetime dose ecstasy 
 
-0.88 
0.77 
0.45 
0.50 
-3.71 
3.31 
2.21 
3.53 
<.01 
<.01 
<.05 
<.01 
V11OxyHb 1 
2 
3 
5.4 
23.4 
48.5 
Lifetime dose ecstasy 
 
 
 
0.52 2.95 <.01 
V4 deoxyHb 1 
2 
3 
0 
7.7 
82.1 
Lifetime dose cannabis 
Recent Cannabis Use  
Lifetime dose ecstasy 
0.47 
-0.75 
0.90 
2.22 
-2.35 
7.02 
<.05 
<.05 
<.001 
S-Letter:       
V3OxyHb 1 
2 
3 
5.7 
13.1 
49.7 
Average alcohol 
Ecstasy frequency 
Lifetime dose ecstasy 
 
-0.54 
0.51 
0.49 
-3.38 
2.99 
2.83 
<.01 
<.01 
<.01 
V4OxyHb 1 
2 
3 
0.4 
31.4 
77.2 
Average alcohol 
Lifetime dose cannabis 
Lifetime dose ecstasy 
Recent Ecstasy Use 
 
-0.87 
1.14 
0.46 
1.14 
-3.63 
4.79 
3.16 
3.62 
<.01 
<.01 
<.01 
<.01 
V4deoxyHb 1 
2 
3 
0.1 
11.6 
85.3 
Lifetime dose cannabis 
Recent Cannabis Use 
Lifetime dose ecstasy 
0.63 
-0.72 
0.89 
3.30 
-2.53 
7.73 
<.01 
<.05 
<.001 
C-Letter       
V3OxyHb 1 
2 
3 
3.3 
7.1 
48.1 
Average alcohol 
Ecstasy frequency 
 
 
-0.57 
0.60 
-3.52 
3.49 
<.01 
<.01 
 
V4OxyHb 1 
2 
3 
0.7 
27.9 
76.6 
Average alcohol 
Lifetime dose cannabis 
Recent Cannabis Use 
Lifetime dose ecstasy 
Recent Ecstasy Use 
-0.96 
1.19 
-1.25 
0.37 
1.32 
-3.94 
4.94 
-3.44 
2.56 
4.12 
<.01 
<.001 
<.01 
<.05 
<.001 
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Figure 1: Anatomical locations of fNIRS channels in relation to prefrontal cortex.  
Reproduced from Kreplin & Fairclough (2013) with permission.  
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Figure 2: Mean oxy-Hb change (µolar) from baseline during the task.  
 
Fig 2: Depicts mean oxy-Hb change (µmolar) from baseline during the CWFT for ecstasy users and non-users, with standard error bars.   
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Figure 3: Mean deoxy-Hb change (µolar) from baseline during the task.  
 
Fig.3: Depicts mean deoxy-Hb change (µmolar) from baseline during the CWFT, with standard error bars.  
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